Screener
Neurocrine Biosciences NBIX Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's invested capital?
- Neurocrine Biosciences (NBIX) reported invested capital of $3.6B in Q1 2026.
- How has Neurocrine Biosciences's invested capital changed year-over-year?
- Neurocrine Biosciences's invested capital increased by 27.2% year-over-year, from $2.83B to $3.6B.
- What is the long-term trend for Neurocrine Biosciences's invested capital?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's invested capital has grown at a 23.6% compound annual growth rate (CAGR), from $1.04B to $3B.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).
Ask your AI about Neurocrine Biosciences's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude